Article
Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA
2 Feb 2023
Abstract excerpt
Recent advances in the development of therapeutic antibodies (Abs) have greatly improved the treatment of otherwise drug-resistant cancers and autoimmune diseases. Antibody activities are mediated by both their Fab and the Fc. However, therapeutic Abs base their protective mechanisms on Fc-mediated effector functions resulting in the activation of innate immune cells by FcRs. Therefore, Fc-bioengineering has been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
